Acute exacerbations of chronic obstructive pulmonary disease: Diagnosis, management, and prevention in critically ill patients

Pharmacotherapy

Volumn 35, Issue 6, 2015, Pages 631-648

  Dixit, Deepali ^a,b   Bridgeman, Mary Barna ^a,b   Andrews, Liza Barbarello ^a,b   Narayanan, Navaneeth ^a,b   Radbel, Jared ^c   Parikh, Amay ^c   Sunderram, Jag ^c  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

chronic obstructive pulmonary disease; COPD; intensive care unit; pulmonary; severe acute exacerbation

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; OXYGEN; ANTIINFECTIVE AGENT;

ACUTE DISEASE; ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE LUNG DISEASE; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CRITICALLY ILL PATIENT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; INVASIVE PROCEDURE; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; PATHOGENESIS; RISK FACTOR; TREATMENT DURATION; VENTILATOR; CRITICAL ILLNESS; DISEASE COURSE; INTENSIVE CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; CRITICAL ILLNESS; DISEASE PROGRESSION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL; RISK FACTORS;

EID: 84931956267     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1599     Document Type: Article

References (61)

1. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH,. COPD surveillance-United States, 1999-2011. Chest 2013; 144: 284-305.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, January 2015. Available from http://www.goldcopd.org/uploads/users/files/GOLD-Report-2015-Jan23.pdf. Accessed February 1, 2015.
3. Johnston AK, Mannino DM,. Epidemiology of COPD exacerbations. In:, Wedzicha JA, Martinez FJ, eds. Exacerbations of chronic obstructive pulmonary disease. London: Informa Healthcare, 2008. 15-26.
4. Suissa S, Dell'Aniello S, Ernst P,. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957-63.
5. Almagro P, Cabrera FJ, Diez J, et al., Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. Chest 2012; 5: 1126-33.
6. Lindenauer PK, Stefan MS, Shieh MS, Pekow PS, Rothberg MB, Hill NS,. Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease. JAMA 2014; 12: 1982-93.
7. Tabak YP, Sun X, Johannes RS, Gupta V, Shorr AF,. Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score. Arch Intern Med 2009; 169: 1595-602.
8. Pearson MG, Allen SC, Barnes G, et al., Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 2: S77-121.
9. Papi A, Luppi F, Franco F, Fabbri M,. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 245-51.
10. Sethi S, Murphy TF,. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-65.
11. Sofer N, Torres A, Ewig S, et al., Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-505.
12. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ,. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med 2006; 32: 1022-9.
13. Hurst JR, Vestbo J, Anzueto A, et al., Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
14. Niewoehner DE, Lokhnygina Y, Rice K, et al., Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131: 20-8.
15. Ai-Ping C, Lee KH, Lim TK,. In hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest 2005; 128: 518-24.
16. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
17. Stefan MS, Shieh MS, Pekow PS, Hill N, Rothberg MB, Lindenauer PK,. Trends in mechanical ventilation among patients hospitalized with acute exacerbation of COPD in the United States, 2001 to 2011. Chest 2015; 147 (4): 959-68. doi: 10.1378/chest.14-1216. [Epub ahead of print].
18. Ram FS, Picot J, Lightowler JV, Wedzicha J,. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease (Update). Cochrane Database Syst Rev 2004; 1: CD004104.
19. Burns KE, Meade MO, Premji A, Adhikari NK,. Noninvasive positive-pressure ventilation as a weaning strategy for intubated adults with respiratory failure. Cochrane Database Syst Rev 2013; 12: CD004127.
20. Burns KE, Meade MO, Premji A, Adhikari NK,. Noninvasive ventilation as a weaning strategy for mechanical ventilation in adults with respiratory failure: a Cochrane systematic review. CMAJ 2014; 3: E112-22.
21. Parrilla FJ, Moran I, Roche-Campo F, Mancebo J,. Ventilatory strategies in obstructive lung disease. Semin Respir Crit Care Med 2014; 4: 431-40.
22. Ranieri VM, Giuliani R, Cinnella G, et al., Physiologic effects of positive end-expiratory pressure in patients with chronic obstructive pulmonary disease during acute ventilatory failure and controlled mechanical ventilation. Am Rev Respir Dis 1993; 1: 5-13.
23. Cameron L, Pilcher J, Weatherall M, Beasley R, Perrin K,. The risk of serious adverse outcomes associated with hypoxaemia and hyperoxaemia in acute exacerbations of COPD. Postgrad Med J 2012; 1046: 684-9.
24. Bertoletti L, Quenet S, Laporte S, et al., Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res 2013; 14: 75.
25. Brulotte CA, Lang ES,. Acute exacerbations of COPD. Emerg Med Clin North Am 2012; 30: 223-47.
26. Dolovich MB, Ahrens RC, Hess DR, et al., Device selection and outcomes of aerosol therapy: evidence-based guidelines. American College of Chest Physicians/American College of Asthma, Allergy and Immunology. Chest 2005; 127: 335-71.
27. Dhand R, Tobin MJ,. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med 1997; 156: 3-10.
28. Ehrmann S, Roche-Campo F, Sferrrazza Papa GF, Isabey D, Brochard L, Apiou-Sbirlea G,. Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med 2013; 39: 1048-56.
29. FOOD and Drug Administration. Phase out of combivent inhalation aerosol: questions and answers. Available from http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm345841.htm. Accessed December 5, 2014.
30. Holland A, Smith F, Penny K, McGrossan G, Veitch L, Nicholson C,. Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units (Review). Cochrane Database Syst Rev 2013; 6: CD008863.
31. Dhand R, Duarte AG, Jubran A, et al., Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care 1996; 154: 388-93.
32. Dellweg D, Wachtel H, Hohn E, et al., In vitro validation of Respimat adapter for delivery of inhaled bronchodilators during mechanical ventilation. J Aerosol Med Pulm Drug Deliv 2011; 24: 285-92.
33. Dzierba AL, Abel EE, Buckley MS, et al., A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome. Pharmacotherapy 2014; 34: 279-90.
34. Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH,. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 9: CD001288.
35. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB,. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010; 303: 2359-67.
36. Leuppi JD, Schuetz P, Bingisser R, et al., Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309: 2223-31.
37. Kiser TH, Allen RR, Valuck RJ, Moss M, Vandivier RW,. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 189: 1052-64.
38. Amaya-Villar R, Garnacho-Montero J, Garcia-Garmendbox drawings light down and lefta JL, et al., Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2005; 31: 157-61.
39. Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley PMA,. Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax 2009; 64: 857.
40. Baker EH, Bell D,. Blood glucose: of emerging importance in COPD exacerbations. Thorax 2009; 64: 830-2.
41. Alía I, de la Cal MA, Esteban A, et al., Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171: 1939-46.
42. Abroug F, Ouanes-Besbes L, Fkih-Hassen M, et al., Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomized evaluation. Eur Respir J 2014; 43: 717-24.
43. Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al., Antibiotics for exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12: CD010257.
44. Mandell LA, Wunderink RG, Anzueto A, et al., Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72.
45. Nouira S, Marghil S, Beighth M, et al., Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomized placebo-controlled trial. Lancet 2001; 358: 2020-5.
46. Quon BS, Gan WQ, Sin DD,. Contemporary management of acute exacerbation of COPD: a systematic and meta-analysis. Chest 2008; 133: 756-66.
47. El Moussaoui R, Roede BM, Speelman P, et al., Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63: 415-22.
48. Schuetz P, Muller B, Christ-Crain M, et al., Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9: CD007498.
49. Schuetz P, Briel M, Mueller B,. Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 2013; 309: 717-8.
50. Stolz D, Christ-Crain M, Bingisser R, et al., Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.
51. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available from http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed December 16, 2014.
52. Wagner B, Filice GA, Drekonja D, et al., Antimicrobial stewardship programs in inpatient hospital settings: a systematic review. Infect Control Hosp Epidemiol 2014; 35: 1209-28.
53. Furumoto A, Ohkusa Y, Chen M,. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26: 4284-9.
54. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, 2015. Available from http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf Accessed February 28, 2015.
55. Lucidarme O, Seguin A, Daubin C, et al., Nicotine withdrawal and agitation in ventilated critically ill patients. Crit Care 2010; 14: R58.
56. Lee AH, Afessa B,. The association of nicotine replacement therapy with mortality in a medical intensive care unit. Crit Care Med 2007; 35: 1517-21.
57. University of Michigan Health System. Tobacco treatment. Ann Arbor, MI: University of Michigan Health System, 2012. Available from http://www.med.umich.edu/1info/FHP/practiceguides/smoking/smoking.pdf. Accessed December 21, 2014.
58. Uzun S, Djamin RS, Kluytmans JAJW, et al., Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomized, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2: 361-8.
59. Albert RK, Connett J, Bailey WC, et al., Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-98.
60. Spruit MA, Singh SJ, Garvey C, et al., An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-64.
61. Garcia-Aymerich J, Monso E, Marrades R, et al., Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2001; 164: 1002-7.